Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We are maintaining our Neutral stance on Endo Pharmaceuticals (ENDP - Analyst Report) with a target price of $44.00.

Headquartered in Chadds Ford, Pennsylvania and founded in 1997, Endo Pharma is a specialty healthcare solutions company. The company, which operates in the US, reports results through three segments: Branded Pharmaceuticals, Generics and Devices and Services. Endo Pharma offers more than 175 products in the areas of pain management, urology and oncology.

In April 2011, Endo Pharma reported its first quarter 2011 results. First quarter adjusted earnings of $1.00 per share were in line with the Zacks Consensus Estimate but $0.26 above the year ago figure.

The year-over-year rise in earnings was attributable to the higher revenues reported in the first quarter of 2011. (Read our full coverage on the earnings report at: Endo Pharma Q1 Result Matches Est.)

We note that Endo Pharma is on an acquisition spree to expand its business. In April 2011, the company announced that it will purchase American Medical Systems , a leading pelvic-health devices provider, for $2.9 billion or $30.00 per share in cash, having completed three major acquisitions in 2010.

We believe that these acquisitions along with the impending purchase of American Medical are steps in the right direction to counter the loss of revenues due to the generic threat hanging over Endo Pharma.

Endo Pharma boasts of a strong product portfolio which should drive growth in the coming quarters. The portfolio was strengthened further by the US launch of Fortesta Gel for treating men (above 18 years of age) with low levels of testosterone (hypogonadism) in March 2011. The entry of Fortesta Gel into the market has widened the treatment options for hypogonadism patients.

The disorder affects approximately 14 million men in the US. However, only approximately 9% are being treated.  In March 2011, Endo received further good news when the US Food and Drug Administration (FDA) approved its oral contraceptive, Emoquette, for the prevention of pregnancy. The approval of the oral contraceptive, the generic version of Johnson & Johnson’s (JNJ - Analyst Report) Ortho-Cept, further strengthens Endo’s portfolio.

However, the lack of near-term catalysts concerns us, especially with its lead product Lidoderm slated to go off patent in 2015. The patent challenge to Lidoderm by Mylan Inc. (MYL - Analyst Report) is another test for Endo Pharma.

Apart from the generic threat, pipeline setbacks like the complete response letter (CRL) received for the new formulation of Opana ER limit the upside potential from current levels. Consequently, we maintain our Neutral recommendation on the stock.

 

 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%